Novo Nordisk

<%= message.delivery.preHeader %>

Your patients might want more from their treatment than it’s currently possible to deliver—but when it comes to hemophilia A treatment, “possible,” is a fast-changing definition.

Let’s examine hemophilia treatment strategies of today, ongoing research for tomorrow, investigational treatment approaches, and consider what all this could mean for your patients living with hemophilia A.

Explore treatment approaches

Is near-normal hemostasis possible?

Consider the possibilities:

We know that

Certain FVIII replacement can maintain factor VIII levels >40% for most of the week, which is in the near-normal to normal range while current FVIII mimetics provide an estimated FVIII level equivalence of approximately 10% to 20% based on modeling and indirect assays.^1,2

reduced thrombin generation, independent of FVIII activity level, has been associated with a more severe bleeding phenotype.³

We’re learning that

depending on the class of therapy, thrombin generation may be one way to measure hemostatic success.^4,5

Discover how current and investigational hemophilia treatment approaches aim to restore thrombin generation and what that could mean for the potential of achieving near-normal hemostasis and helping your patients overcome treatment trade-offs.

Find out more

STAY UP TO DATE

Want to get more updates and communications on hemophilia A from Novo Nordisk as they become available?

References:

1.	ALTUVIIIO^® Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA.
2.	Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024;30 Suppl 3:39-44.
3.	Verhagen MJA, van Balen EC, Blijlevens NMA, et al. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease. J Thromb Haemost. 2024;22(1):152-162.
4.	Sidonio RF Jr, Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: a narrative review. Res Pract Thromb Haemost. 2022;7(1):100018.
5.	Bernardo Á, Caro A, Martínez-Carballeira D, et al. Applicability of the thrombin generation test to evaluate the hemostatic status of hemophilia A patients in daily clinical practice. J Clin Med. 2022;11(12):3345.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.